Recombinant Xenopus laevis Activin receptor type-2B (acvr2b)

What is the basic structure and function of Xenopus laevis ACVR2B?

Xenopus laevis ACVR2B is a type II transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. The receptor consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain. Structurally, it fulfills all criteria of a transmembrane protein serine kinase . Functionally, ACVR2B binds to Activin A, which then recruits and phosphorylates type I Activin receptors such as ALK4 or ALK7, subsequently activating the SMAD2/3 signaling pathway . This pathway plays crucial roles in regulating cell proliferation, differentiation, and migration during embryonic development in Xenopus.

How does Xenopus ACVR2B differ from mammalian homologs?

While the core functional domains of ACVR2B are conserved across species, Xenopus laevis ACVR2B exhibits specific amino acid variations that may affect ligand binding affinity and downstream signaling efficiency. The extracellular domain shows approximately 85-90% sequence homology with mammalian homologs, while the kinase domain demonstrates higher conservation (>90% homology). These differences should be considered when extrapolating findings from Xenopus to mammalian systems. The developmental context of Xenopus also provides unique advantages for studying ACVR2B function in mesoderm induction and patterning that may not be as readily accessible in mammalian models .

What physiological processes in Xenopus development are regulated by ACVR2B signaling?

ACVR2B signaling in Xenopus regulates several critical developmental processes:

• Mesoderm induction and patterning

• Dorsal-ventral axis formation

• Muscle development and differentiation

• Neural tissue specification

Experimental evidence demonstrates that embryos injected with activin receptor RNA display developmental defects characterized by inappropriate formation of dorsal mesodermal tissue, confirming ACVR2B's role in these processes . The receptor mediates concentration-dependent cellular responses, with specific thresholds of activin binding triggering distinct gene expression patterns (e.g., Xbra vs. Xgsc transcription) .

What expression systems are most effective for producing recombinant Xenopus ACVR2B?

For functional recombinant Xenopus laevis ACVR2B production, several expression systems can be utilized, each with distinct advantages:

For functional studies, mammalian expression systems like HEK293 cells are preferred as they provide proper folding and post-translational modifications . When expressing the extracellular domain (residues 19-134 in human ACVR2B), inclusion of a secretion signal and appropriate tag (His, Fc) facilitates purification and detection .

What are the optimal purification strategies for recombinant Xenopus ACVR2B?

Purification of recombinant Xenopus ACVR2B typically involves a multi-step process:

• Initial Capture: For His-tagged constructs, immobilized metal affinity chromatography (IMAC) using Ni-NTA or Co2+ resins. For Fc-tagged constructs, Protein A/G affinity chromatography.

• Intermediate Purification: Ion exchange chromatography (typically anion exchange at pH 8.0) to remove contaminants with different charge properties.

• Polishing: Size exclusion chromatography (SEC) to achieve >95% purity and remove aggregates.

For optimal results, include 5-10% glycerol and 1-2 mM DTT in all buffers to maintain protein stability. Final formulation in 20 mM phosphate buffer with 150 mM NaCl, pH 7.4 is suitable for most applications . SEC-HPLC can be used to confirm purity >90%, and functional validation via ELISA binding assays is recommended to ensure proper folding and activity .

How can I assess the quality and functionality of purified recombinant Xenopus ACVR2B?

Multiple complementary methods should be employed to validate recombinant Xenopus ACVR2B:

• Purity assessment:

  • SDS-PAGE with Coomassie staining (target: >95% purity)

  • SEC-HPLC analysis (target: >90% monodisperse peak)

• Identity confirmation:

  • Western blotting with anti-ACVR2B antibodies

  • Mass spectrometry for precise molecular weight determination

• Functional validation:

  • Binding ELISA with known ligands (Activin A)

  • Surface Plasmon Resonance (SPR) for kinetic binding parameters

  • BMP binding assays (BMP-9, BMP-10) to assess receptor specificity

• Structural integrity:

  • Circular dichroism spectroscopy

  • Thermal shift assay to determine protein stability

For functional validation, one standard approach is measuring binding ability in an ELISA format, where immobilized ACVR2B (2 μg/ml) should bind to anti-ACVR2A&ACVR2B recombinant antibodies with EC50 values of approximately 3-4 ng/mL .

How can recombinant ACVR2B be used to study mesoderm induction in Xenopus?

Recombinant ACVR2B can be utilized in several experimental paradigms to study mesoderm induction:

• Animal cap assays: Treat isolated animal caps with varying concentrations of recombinant ACVR2B-Fc to sequester endogenous activins, then assess mesoderm marker expression (e.g., Xbra, Xgsc) via RT-PCR or in situ hybridization. This allows quantification of the receptor's role in mesoderm specification.

• mRNA microinjection: Inject synthetic mRNA encoding wild-type or mutant ACVR2B into specific blastomeres at early cleavage stages, then analyze developmental outcomes. Research has demonstrated that embryos injected with activin receptor RNA show increased sensitivity to activin, measurable through muscle actin RNA induction .

• Receptor-ligand interaction studies: Utilize recombinant ACVR2B in conjunction with labeled activins to determine binding thresholds and receptor occupancy in relation to differential gene expression. This builds on findings that Xenopus blastula cells sense activin concentration by assessing the absolute number of occupied receptors per cell (approximately 100 and 300 molecules of bound activin activate Xbra and Xgsc transcription, respectively) .

• Chimeric receptor studies: Create chimeric receptors combining Xenopus ACVR2B with mammalian domains to identify species-specific signaling properties in mesoderm induction contexts.

What methods can quantify ACVR2B-mediated SMAD2/3 signaling in Xenopus embryos?

Several techniques can effectively quantify ACVR2B-mediated SMAD2/3 signaling:

• Nuclear SMAD2 quantification: Isolate nuclei from animal cap cells and quantify nuclear SMAD2 protein levels using Western blotting or immunofluorescence. Research has shown that injection of 0.2 or 0.6 ng of Smad2 mRNA activates Xbra or Xgsc transcription, respectively (a 3-fold difference that mirrors activin thresholds) .

• Phospho-SMAD2/3 detection: Use phospho-specific antibodies to detect activated SMAD2/3 via Western blotting or ELISA. Quantify the ratio of phosphorylated to total SMAD proteins to assess signaling intensity.

• SMAD-responsive reporter assays: Inject SMAD-responsive luciferase reporters (containing SMAD binding elements) into embryos or animal caps, then measure luciferase activity in response to various treatments.

• Live imaging with fluorescent biosensors: Utilize FRET-based biosensors to visualize SMAD2/3 activation dynamics in real-time within living embryonic tissues.

• ChIP-seq analysis: Perform chromatin immunoprecipitation followed by sequencing to identify SMAD2/3 binding sites genome-wide after ACVR2B activation, revealing target genes and regulatory networks.

How does receptor density affect Xenopus ACVR2B signaling and developmental outcomes?

Receptor density plays a critical role in ACVR2B signaling through several mechanisms:

• Threshold-dependent gene activation: Quantitative analysis has revealed that Xenopus blastula cells sense activin concentration by assessing the absolute number of occupied receptors per cell. Remarkably, only a 3-fold difference in receptor occupancy (100 versus 300 molecules of bound activin) determines whether Xbra or Xgsc is activated, demonstrating the precision of this system .

• Morphogen gradient interpretation: ACVR2B density affects cells' ability to interpret activin/nodal morphogen gradients during gastrulation. Higher receptor density increases sensitivity to ligands, resulting in activation of more "dorsal" gene expression programs at lower ligand concentrations.

• Signal duration effects: Higher receptor density not only increases signal amplitude but also prolongs signaling duration by maintaining a pool of unoccupied receptors that can continue signaling as internalized receptors are degraded.

• Relationship to SMAD levels: The relationship between receptor occupancy and nuclear SMAD accumulation is non-linear. Experimental evidence indicates that injection of 0.2 or 0.6 ng of Smad2 mRNA activates Xbra or Xgsc transcription respectively, paralleling the 3-fold difference seen with receptor occupancy .

For experimental manipulation, receptor density can be controlled through titrated mRNA injection or using inducible expression systems, allowing precise correlation between receptor levels and developmental outcomes.

How can chimeric ACVR2B constructs be designed to study receptor domain functions?

Chimeric ACVR2B constructs provide powerful tools for dissecting domain-specific functions:

• Extracellular domain swaps: Replace the Xenopus ACVR2B extracellular domain with corresponding regions from ACVR2A, BMPR2, or mammalian ACVR2B to investigate ligand-binding specificity. This approach can reveal why ACVR2B displays 3-4 fold higher affinity for activin ligands compared to ACVR2A .

• Transmembrane domain substitutions: Exchange the transmembrane domain with those from other receptors to study membrane localization, receptor clustering, and interactions with membrane-associated factors.

• Kinase domain chimeras: Create constructs with kinase domains from different species or related receptors to investigate phosphorylation patterns and substrate preferences.

• Reporter fusion proteins: Generate ACVR2B fusions with fluorescent proteins (GFP, mCherry) at specific locations to track receptor trafficking, clustering, and internalization in live embryonic cells without disrupting function.

For optimal design, maintain the natural boundaries between protein domains and include flexible linker sequences (e.g., GGGGS repeats) between domains. Express chimeric constructs in Xenopus embryos via microinjection of synthetic mRNA (50-200 pg) at the 1-2 cell stage, and validate expression by Western blotting before proceeding to functional assays.

What strategies can distinguish between ACVR2B-mediated BMP and Activin/Nodal signaling pathways?

Distinguishing between ACVR2B-mediated BMP and Activin/Nodal signaling requires sophisticated experimental approaches:

• Pathway-specific inhibitors:

  • For activin/nodal pathway: Use SB-431542 (inhibits ALK4/5/7)

  • For BMP pathway: Use LDN-193189 (inhibits ALK2/3)

  • Observe differential effects on ACVR2B-mediated responses

• Pathway-specific SMAD reporters:

  • SMAD2/3-specific reporters for activin/nodal pathway

  • SMAD1/5/8-specific reporters for BMP pathway

  • Co-inject with recombinant ACVR2B constructs

• Co-immunoprecipitation studies:

  • Pull-down ACVR2B and analyze association with type I receptors (ALK4/7 for activin/nodal; ALK3/6 for BMP)

  • Quantify relative association under different ligand treatments

• Epistasis experiments:

  • Co-express ACVR2B with constitutively active or dominant-negative versions of downstream components

  • Example: Constitutively active ALK3 (BMP pathway) versus ALK4 (activin/nodal pathway)

This approach is particularly important because research has shown that while BMPs have low affinity for ACVR2/ACVR2B, they can nevertheless utilize these receptors for signaling because they bind first to type 1 receptors (ALK3 or ALK6) and then engage type 2 receptors . This promiscuity has implications for interpreting results of receptor manipulation experiments.

How can genome editing approaches be used to study ACVR2B function in Xenopus?

CRISPR/Cas9 and other genome editing technologies offer powerful approaches for studying ACVR2B function in Xenopus:

• Complete knockout studies:

  • Design sgRNAs targeting early exons of ACVR2B

  • Inject Cas9 protein with sgRNAs into fertilized eggs

  • Verify editing efficiency via T7 endonuclease assay or deep sequencing

  • Analyze developmental phenotypes focusing on mesoderm formation and axis specification

• Domain-specific mutations:

  • Create point mutations in key functional residues using homology-directed repair

  • Target conserved kinase domain residues (e.g., ATP-binding site, substrate recognition regions)

  • Examine effects on SMAD2/3 phosphorylation and target gene expression

• Knock-in approaches:

  • Generate epitope-tagged or fluorescent protein fusions at endogenous loci

  • Create conditional alleles using Cre/loxP or similar systems adapted for Xenopus

  • Perform lineage-specific functional analysis

• Paralog compensation analysis:

  • Simultaneously target ACVR2A and ACVR2B to overcome potential redundancy

  • Compare single versus double knockout phenotypes

  • Rescue experiments with wild-type or mutant mRNAs to test specificity

Note that in Xenopus laevis, which is allotetraploid, you must consider targeting both homeologs (L and S forms) of ACVR2B for complete loss-of-function. Verification of protein loss should be performed via Western blot or immunostaining before phenotypic interpretation.

What are common issues in recombinant Xenopus ACVR2B expression and how can they be resolved?

When expressing recombinant Xenopus ACVR2B, researchers frequently encounter several challenges:

For extracellular domain constructs (typically residues 19-134), expression in HEK293 cells followed by purification via affinity chromatography (His-tag) and size exclusion typically yields properly folded, functional protein .

How can ACVR2B activity be preserved during storage and experimental manipulation?

Maintaining ACVR2B stability and activity requires careful attention to storage and handling conditions:

• Short-term storage (1-2 weeks):

  • Store at 4°C in 20 mM phosphate buffer, 150 mM NaCl, pH 7.4

  • Include stabilizers: 5-10% glycerol, 1 mM DTT or 0.1 mM TCEP

  • Filter-sterilize (0.22 μm) to prevent microbial growth

• Long-term storage:

  • Aliquot and store at -80°C (avoid repeated freeze-thaw cycles)

  • Lyophilization in the presence of cryoprotectants (sucrose, trehalose)

  • Concentration should not be less than 100 μg/ml to prevent adsorption losses

• Thawing and handling:

  • Thaw rapidly at room temperature with gentle agitation

  • Centrifuge briefly (10,000 x g, 5 min) to remove any precipitates

  • Avoid vortexing; mix by gentle inversion or pipetting

• Activity assessment:

  • Perform binding activity assays before and after storage periods

  • Use SEC-HPLC to monitor for aggregation or degradation

  • For Fc-fusion constructs, verify Fc functionality via Protein A/G binding

For functional studies in Xenopus embryos, freshly thawed protein should be used within 24 hours for optimal results, and freeze-thaw cycles should be strictly limited to maintain consistent activity levels.

What controls are essential for interpreting ACVR2B functional studies in Xenopus embryos?

Rigorous experimental design requires appropriate controls when studying ACVR2B in Xenopus:

• Negative controls:

  • Uninjected embryos to establish baseline development

  • Injection of irrelevant protein/mRNA (e.g., GFP) to control for injection effects

  • Heat-inactivated recombinant ACVR2B to control for non-specific protein effects

  • Non-binding mutant ACVR2B (ligand-binding domain mutations) to verify specificity

• Positive controls:

  • Known ACVR2B ligands (Activin A) to confirm receptor responsiveness

  • Constitutively active downstream components (ca-ALK4, ca-SMAD2) to validate pathway functionality

  • Previously characterized ACVR2B constructs with established phenotypes

• Dosage controls:

  • Titration series of ACVR2B mRNA (0.1-2 ng) to establish dose-response relationships

  • Careful quantification of injected material (fluorescent tracer co-injection)

  • Internal standards for qPCR analysis of target gene expression

• Spatial controls:

  • Targeted injections to specific blastomeres with lineage tracers

  • Comparison of effects in different germ layers/regions

  • Uninjected sides of embryos as internal controls in unilateral injections

When interpreting results, remember that Xenopus blastula cells respond to small differences in activin receptor signaling levels—a mere 3-fold difference in receptor occupancy (100 vs. 300 molecules) determines whether Xbra or Xgsc is activated . This highlights the importance of precise quantitative controls in these experiments.

How does ACVR2B signaling integrate with other pathways during Xenopus development?

Current research is revealing complex crosstalk between ACVR2B and other signaling networks:

• ACVR2B-Wnt pathway integration:

  • ACVR2B/Nodal signaling modulates β-catenin stability and localization

  • Wnt signals can affect ACVR2B expression and availability through feedback mechanisms

  • Co-immunoprecipitation studies can identify physical interactions between pathway components

• ACVR2B-BMP balance in mesodermal patterning:

  • Muscle growth is regulated by a balance between MSTN/activin A signaling and BMP signaling

  • BMPs utilize multiple type 2 receptors for signaling, including activin type 2 receptors (ACVR2B)

  • This may explain why targeting type I receptors (ALK4/5) can produce stronger phenotypes than targeting type II receptors (ACVR2/ACVR2B)

• ACVR2B in FGF-mediated mesoderm maintenance:

  • ACVR2B initiates mesoderm formation while FGF signaling maintains it

  • Temporal dynamics can be studied using inducible ACVR2B constructs

  • Dual-inhibition experiments reveal synergistic effects

• Hippo pathway interactions:

  • Emerging evidence suggests ACVR2B-SMAD signaling converges with YAP/TAZ activity

  • These interactions regulate differentiation versus proliferation decisions

For experimental investigation, combinatorial perturbation approaches followed by RNA-seq or phospho-proteomics can map pathway integration at the systems level.

What role does ACVR2B play in regeneration and tissue homeostasis in Xenopus?

ACVR2B has emerging roles in regeneration contexts that present opportunities for innovative research:

• Tail regeneration:

  • ACVR2B expression is dynamically regulated during tail regeneration

  • Tissue-specific conditional knockout or overexpression can reveal stage-specific functions

  • Live imaging of ACVR2B-fluorescent protein fusions during regeneration

• Limb regeneration:

  • Comparison of ACVR2B activity in regeneration-competent stages versus refractory stages

  • Manipulation of ACVR2B signaling may restore regenerative capacity in non-regenerative contexts

  • ACVR2B-Fc treatment can be used to sequester ligands during specific regeneration phases

• Tissue homeostasis:

  • ACVR2B regulates muscle mass through myostatin/GDF11 signaling

  • Administration of ACVR2B-Fc can increase muscle mass by more than 50% in just two weeks in some animal models

  • Cell-type specific perturbation using tissue-specific promoters can dissect direct versus indirect effects

• Metamorphosis:

  • ACVR2B signaling during tadpole-to-frog transition

  • Interaction with thyroid hormone signaling pathways

  • Potential role in tissue remodeling and organ development

These research directions benefit from the unique advantages of Xenopus as a model system, including external development, accessible embryology, and remarkable regenerative capabilities at certain life stages.

How can systems biology approaches enhance our understanding of ACVR2B signaling networks?

Systems biology offers powerful frameworks for comprehensively analyzing ACVR2B networks:

• Quantitative phospho-proteomics:

  • Map the complete phosphorylation cascade downstream of ACVR2B

  • Identify non-canonical targets beyond SMAD2/3

  • Temporal dynamics of signaling after ligand binding

• Single-cell transcriptomics:

  • Cell-type specific responses to ACVR2B activation

  • Heterogeneity in pathway activation within tissues

  • Trajectory analysis to follow developmental decisions

• Network modeling:

  • Ordinary differential equation models of ACVR2B pathway dynamics

  • Parameter fitting using quantitative data on receptor occupancy and SMAD nuclear accumulation

  • In silico prediction of pathway behavior under perturbations

• Multi-omics integration:

  • Correlation of ACVR2B-regulated transcriptome, proteome, and epigenome

  • Identification of feedback and feed-forward regulatory circuits

  • Mapping of enhancer activation in response to ACVR2B signaling

These approaches can help explain the remarkable finding that Xenopus blastula cells can discriminate between small differences in ACVR2B occupancy (100 versus 300 molecules) to initiate completely different developmental programs , a precision that remains incompletely understood at the systems level.